VEGF-A is the most potent angiogenic factor in tumour angiogenesis. Its effects are mediated via two receptors VEGFR-1 and VEGFR-2. Primary aim of our study was to examine the expression of VEGFR-1 in breast cancer and its correlation to VEGF expression, lymph node status, tumour size, histological grade, and hormone receptor status. To examine the VEGFR-1 and VEGF expressions in tumour and sur...

OBJECTIVE Vascular endothelial growth factor (VEGF) plays critical roles in the regulation of angiogenesis and lymphangiogenesis. However, tissue edema, hemorrhage, and inflammation occur when VEGF-A is used for angiogenic therapy. To design a novel angiogenic factor without severe side effects, we examined the biological function of chimeric VEGF-E(NZ7)/placental growth factor (PlGF), which is...

The acute increase in vascular permeability produced by vascular endothelial growth factor (VEGF-A(165)) requires activation of endothelial Flk-1 receptors (VEGFR-2) and stimulation of platelet-activating factor (PAF) synthesis. Like PAF, VEGF-A(165) promotes translocation of P-selectin to the endothelial cell (EC) surface. However, the mechanisms involved remain unknown. By treating human umbi...

Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) have crucial roles in both physiological and pathological angiogenesis. The VEGF family consists of VEGF-A (generally called VEGF), VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF). These peptides show different affinities for VEGFR subtypes. VEGFR exists as three subtypes, VEGFR-1, VEGFR-2, and VEGFR-3, and is struc...

BACKGROUND Vascular endothelial growth factor receptor-2 (VEGFR-2, KDR), a receptor tyrosine kinase, regulates mitogenic, chemotactic, hyperpermeability, and survival signals in vascular endothelial cells in response to its ligand vascular permeability factor/ vascular endothelial growth factor (VPF/VEGF). SHP-1 is a protein tyrosine phosphatase known to negatively regulate signaling from recep...

*Both authors contributed equally. Dept. Biochemical Sciences "A. Rossi Fanelli", CNR Institute of Molecular Biology and Pathology, and Istituto Pasteur-Fondazione Cenci Bolognetti, University "La Sapienza", Piazzale Aldo Moro 5, 00185 Rome, Italy Molecular and Cell Biology and Molecular Oncology Laboratory, IDI-IRCCS, via Monti di Creta 104, 00167 Rome, Italy Dept. Molecular Biology, Universit...

Vascular endothelial growth factor receptors (VEGFRs) are receptor tyrosine kinases (RTKs) that regulate proliferation, migration, angiogenesis and vascular permeability of endothelial cells. Vascular endothelial growth factor receptor 1 (VEGFR1) and receptor 2 (VEGFR2) bind vascular endothelial growth factors (VEGFs), inducing receptor dimerisation and activation, characterised by phosphorylat...

OBJECTIVE Liver X receptors (LXRα, LXRβ) are master regulators of cholesterol homeostasis. In the endothelium, perturbations of cell cholesterol have an impact on fundamental processes. We, therefore, assessed the effects of LXR activation on endothelial functions related to angiogenesis in vitro and in vivo. METHODS AND RESULTS LXR agonists (T0901317, GW3965) blunted migration, tubulogenesis...

cooperate with VEGFR-3 in lymphatic endothe-lial cell migration and proliferation. Whereas VEGF-C is essential in mouse lymphatic vascu-lar development, it remains to be resolved to what extent the lack of VEGFR-2 binding accounts for the dispensable role of VEGF-D in this process. 5,6 Elucidation of the receptor-binding pattern of Xenopus VEGF-D and finding whether it explains the functional d...

Kallistatin is a plasma protein with anti-inflammatory properties. In this study, we investigated the role and mechanisms of kallistatin in inhibiting endothelial inflammation through its heparin-binding domain. We showed that recombinant wild-type kallistatin dose-dependently competed with tumor necrosis factor (TNF)binding to TNFreceptor in endothelial cells, whereas kallistatin mutant at the...